Bacterial Infection Due to Helicobacter Pylori (H. Pylori) Clinical Trial
Official title:
Reinfection After Eradication of Helicobacter Pylori Infection in Adult :A National Multicentre Study
Helicobacter pylori is closely related with gastritis, peptic ulcer, gastric cancer and gastric MALT lymphoma, and it may participate in a variety of parenteral diseases. Infection rates of Helicobacter pylori is still high, so effectively eradication is necessary. At present, the eradication therapy has achieved very good curative effect. However, relapse after eradication is unoptimistic. This study has made an analysis for reinfection after eradication of Helicobacter pylori Infection include the retrospective and prospective studies, aims to explore the epidemiological data and related risk factors of Hp reinfection in China.
In the retrospective study,we choose the people received regular eradication therapy, successfully eradicated helicobacter pylori more than six months, but 4 to 8 weeks after drug withdrawal ,the detection result of helicobacter pylori were negative to ensure that the results of the study is the reinfection, not residual. Even more noteworthy is during the treatment and detection again, the patients must not received any eradication therapy of Hp. What's more , before the detection, they also has not used antibiotics, bismuth agent and the traditional Chinese medicine with antibacterial effect in 1 monthor and has not used H2RA and PPI in 2 weeks to prevent affecting the accuracy of the results. At the same time, we also investigated the patient's general situation, conomic conditions, living conditions, personal health and lifestyle to explore related risk factors of Hp reinfection in China. In the prospective study, we detected Hp by C-UBT after regular eradication therapy of Hp for 4 weeks, 8 weeks and 6 months to prospect the reinfection of Hp.It also can make up the defects of retrospective study. ;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02553083 -
High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection
|
Phase 4 | |
| Completed |
NCT01897909 -
The Impact of Helicobacter Pylori Infection on Immune Regulation and Clinical Course in HIV Patients in Ghana
|
||
| Completed |
NCT02160860 -
Epidemiology of Helicobacter Pylori Infection Among Shanghai Children
|
N/A | |
| Completed |
NCT03367897 -
Bleeding Ulcer and Erosions Study "BLUE Study"
|
||
| Completed |
NCT01506986 -
Helicobacter Eradication Aspirin Trial
|
Phase 4 | |
| Recruiting |
NCT01572597 -
Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy
|
Phase 4 | |
| Recruiting |
NCT02164409 -
Changes Associated With H. Pylori and Gastric Carcinogenesis
|
||
| Completed |
NCT01623154 -
POCone-UBiT-IR300 Pediatric Comparison Study
|
Phase 4 | |
| Completed |
NCT01591486 -
Helicobacter Pylori and the Long-term Risk of Peptic Ulcer Bleeding
|
N/A | |
| Completed |
NCT03124199 -
Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection
|
Phase 3 | |
| Completed |
NCT02092506 -
RCT: Triple vs Sequential vs Concomitant Therapy H Pylori
|
Phase 4 | |
| Completed |
NCT01902589 -
Resistance of Helicobacter Pylori to Antibiotics in Children
|
N/A |